Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Hones OTCs As “Sharp End” Of Consumer Products Business

This article was originally published in The Tan Sheet

Executive Summary

Glaxo’s OTC business is “the very best end of consumer goods as opposed to being a poor relation of pharmaceuticals,” says Emma Walmsley, GSK Consumer Healthcare president.

You may also be interested in...



Glaxo Launches Flonase OTC, Banks On More Consumer Growth Drivers

CEO Andrew Witty says the consumer business GSK is forming through brand divestitures and its JV with Novartis is a part of “the company I've been trying to create for seven years.” GSK’s OTC Flonase reached U.S. stores Feb. 3, a sign of additional product launches he expects the consumer health JV to do.

Glaxo Launches Flonase OTC, Banks On More Consumer Growth Drivers

CEO Andrew Witty says the consumer business GSK is forming through brand divestitures and its JV with Novartis is a part of “the company I've been trying to create for seven years.” GSK’s OTC Flonase reached U.S. stores Feb. 3, a sign of additional product launches he expects the consumer health JV to do.

Emerging Markets Drive Consumer Health Growth, Pose Challenges

Developing markets account for 50% of the global self-care product sales, but close to 100% of the sector’s growth, according to market research firm IMS Health. This picture will continue as OTC drugs and dietary supplements have a bigger health care role in developing countries than in developed markets.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS142351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel